 SOMERVILLE, Mass., Oct. 05, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or Finch Therapeutics Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Samuel Allen Al Hamood has joined Finchs Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance, business development, corporate strategy, and MA across several global industry sectors. 